Historical data shows that a consistent $500 monthly investment into Sonnet BioTherapeutics Holdings, Inc. (SONN) starting in 2020 would have turned a total investment of $46K into $6K today. This represents a total return of -87.5% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
Sonnet BioTherapeutics Holdings, Inc. does not currently pay a notable dividend. For growth-focused stocks like SONN, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $6K without the need for dividend reinvestment.
SONN vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,SONN underperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $83K, compared to SONN's $6K.